JPRN-UMIN000027550已完成未知
An Evaluation of tumor response to osimertinib by early FDG-PET finding in patients with T790M positive EGFR mutated non-small cell lung cancer - Usefulness of early PET examination in pateients treated with osimertinib
Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, 3-1-1, Asahi Matsumoto, 390-8621, Japan,0 个研究点目标入组 30 人开始时间: 2017年6月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.past history of hypersensitivity to drugs; 2.Double cancers, 3.Severe complications (for example, heart failure, renal failure, liver failure, severe diabetes mellitus, etc.); 4.Active infection including hepatitis B, hepatitis C and HIV. 5.Interstitial lung disease detectable on chest radiography or past history of interstitial lung disease during prior EGFR-TKIs therapy; 6.Pleural, pericardial, or peritoneal effusion requiring drainage; 7.Active brain metastasis; 8.Pregnancy or female with planning pregnancy. Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry 9.Any of the following cardiac criteria: -Mean resting corrected QT interval: >470 msec, -Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block) -Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval. 10. Treatment history of immune-check point inhibitors
研究者
相似试验
招募中
4 期
Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2)2024-517424-18-00Fondazione Policlinico Universitario Agostino Gemelli IRCCS54
进行中（未招募）
1 期
Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabolic response to osimertinibon-small-cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-005121-21-DEniversitätsklinikum Essen20
已完成
不适用
Observational study of osimertinib for patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous EGFR-TKI therapy(WJOG8815LFS)EGFR mutation positive advanced or metastatic NSCLCJPRN-UMIN000034682West Japan Oncology Group33
已完成
不适用
A phase II study of osimertinib in patients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerPatients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerJPRN-UMIN000027655Division of Thoracic Oncology, Shizuoka cancer center18
招募中
不适用
Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinibon-small cell lung cancerJPRN-UMIN000028166Asahikawa Medical University Hospital50